|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.55 USD | +1.79% |
|
+1.75% | +0.14% |
| 17/04 | Sarepta Therapeutics Seen Benefiting From New Elevidys Study, Better US Uptake in Second Half of 2026 | MT |
| 16/04 | Roche Plans New Trial for Muscular Dystrophy Therapy to Seek EU Approval | DJ |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Gene Research and Development | ||||||||||
Discovering, Developing, Manufacturing and Delivering Therapies | 70Cr | 93Cr | 124.33Cr | 190.2Cr | 219.82Cr | |||||
Total Assets | 314.8Cr | 312.84Cr | 326.46Cr | 396.32Cr | 334.97Cr | |||||
Interest Expense | -6.35Cr | -5.32Cr | -2.2Cr | -1.84Cr | -3.81Cr | |||||
Income Tax Expense | -2L | 1.35Cr | 1.59Cr | 2.55Cr | 1.12Cr | |||||
CAPEX | -3.85Cr | -3.08Cr | -7.61Cr | -14Cr | -10Cr | |||||
EBT | -42Cr | -69Cr | -52Cr | 26Cr | -70Cr | |||||
D&A | 3.79Cr | 4.18Cr | 4.44Cr | 3.77Cr | 4.45Cr | |||||
Operating Income | -46Cr | -54Cr | -27Cr | 22Cr | -70Cr | |||||
Net Income | -42Cr | -70Cr | -54Cr | 24Cr | -71Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 70Cr | 93Cr | 124.33Cr | 190.2Cr | 219.82Cr | |||||
Total Assets | 314.8Cr | 312.84Cr | 326.46Cr | 396.32Cr | 334.97Cr | |||||
Interest Expense | -6.35Cr | -5.32Cr | -2.2Cr | -1.84Cr | -3.81Cr | |||||
Income Tax Expense | -2L | 1.35Cr | 1.59Cr | 2.55Cr | 1.12Cr | |||||
D&A | 3.79Cr | 4.18Cr | 4.44Cr | 3.77Cr | 4.45Cr | |||||
CAPEX | -3.85Cr | -3.08Cr | -7.61Cr | -14Cr | -10Cr | |||||
Net Income | -42Cr | -70Cr | -54Cr | 24Cr | -71Cr | |||||
EBT | -42Cr | -69Cr | -52Cr | 26Cr | -70Cr | |||||
Operating Income | -46Cr | -54Cr | -27Cr | 22Cr | -70Cr |
- Stock Market
- Equities
- SRPT Stock
- Financials Sarepta Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition